CRSP has been the topic of several other research reports. Roth Capital upped their price objective on shares of Crispr Therapeutics from $50.00 to $65.00 in a report on Tuesday, July 30th. Piper Jaffray Companies reiterated an “overweight” rating on shares of Crispr Therapeutics in a research note on Monday, October 21st. BTIG Research upped their target price on shares of Crispr Therapeutics from $51.00 to $59.00 and gave the stock a “positive” rating in a research note on Tuesday, July 30th. Needham & Company LLC reiterated a “buy” rating and issued a $62.00 target price on shares of Crispr Therapeutics in a research note on Wednesday, July 31st. Finally, BidaskClub upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, October 31st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $69.54.
Shares of Crispr Therapeutics stock opened at $68.11 on Friday. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $3.63 billion, a PE ratio of -19.80 and a beta of 3.15. The firm’s 50 day moving average is $48.67 and its 200 day moving average is $45.94.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The firm had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. As a group, research analysts anticipate that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total value of $390,000.00. Following the sale, the director now owns 7,500 shares in the company, valued at $390,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock worth $3,620,760 over the last quarter. Company insiders own 21.40% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. Nikko Asset Management Americas Inc. grew its holdings in Crispr Therapeutics by 48.4% in the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after purchasing an additional 906,006 shares during the period. ARK Investment Management LLC raised its position in Crispr Therapeutics by 34.7% in the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after purchasing an additional 701,332 shares during the period. Price T Rowe Associates Inc. MD raised its position in Crispr Therapeutics by 19.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after purchasing an additional 121,176 shares during the period. Wells Fargo & Company MN raised its position in Crispr Therapeutics by 23.9% in the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after purchasing an additional 116,540 shares during the period. Finally, Orbimed Advisors LLC purchased a new stake in Crispr Therapeutics in the third quarter valued at $21,167,000. 49.81% of the stock is owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Bond
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.